poLight ASA Receives Follow-on Purchase Order for TLens® for AR|MR Use from a Leading Consumer OEM
poLight ASA Receives Follow-on Purchase Order for TLens® for AR|MR Use from a Leading Consumer OEM
Tønsberg, Norway 24 November 2025 - poLight ASA (OSE: PLT) today announced
that the company has over the last week received several follow-on purchase
orders with a total approximate worth of NOK 0.9 million to supply TLens® to a
leading consumer OEM for an AR|MR application.
"We are excited to see the progress on this mature proof-of-concept program.
There is still a way to go, but the number of TLens® ordered at this stage is
clearly a promising sign and show a clear intention.," said Dr. Øyvind
Isaksen, CEO of poLight ASA. "We continue to see strong and growing interest
in TLens® for AR|MR applications. Low power, ultrafast, small form-factor
autofocus functionality is critical to delivering the promise of AI-driven
imaging that replicates the human eye. By addressing these design challenges,
we look forward to playing a role that unlocks AR|MR's true potential."
The delivery of TLens® product is expected to be completed in Q4 2025.
For further information, please contact:
Dr Øyvind Isaksen, CEO, poLight ASA: +47 90 87 63 98
About poLight ASA
poLight ASA (listed on the Oslo Stock Exchange: PLT) offers a patented,
proprietary tunable optics technology, starting with its first product, TLens®
which replicates "the human eye" experience in autofocus cameras used in
devices such as smartphones, wearables, barcode scanners, machine vision
systems and various medical equipment. poLight's TLens® enables better system
performance and new user experiences due to benefits such as extremely fast
focus, small footprint, no magnetic interference, low power consumption and
constant field of view. poLight is based in Tønsberg, Norway, with employees
in Finland, France, UK, US, China, Taiwan, Japan, and the Philippines. For
more information, please visit https://www.polight.com
(https://www.polight.com/)
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2025-11-24 08:43
CET.